GLP1R and diabetes mellitus: Liraglutide, the first long-acting GLP-1 RA based on the human GLP-1 sequence, has been well-detailed in the Liraglutide Effect and Action in Diabetes (LEAD) study program of randomized controlled trials, which explored the efficacy and safety of once daily subcutaneous injections of Liraglutide 1.2–1.8 mg as monotherapy, or in combination with other oral antidiabetic agents [13,14,15,16,17,18].